Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 clinical trial for Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

Phase 3 clinical trial for Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daraxonrasib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RASolute 303

Most Recent Events

  • 10 Nov 2025 New trial record
  • 05 Nov 2025 According to Revolution Medicines media release, company expects to share updated daraxonrasib monotherapy and daraxonrasib plus GnP combination data, each in patients with first line PDAC, including preliminary durability, in the first half of 2026.
  • 10 Sep 2025 According to Revolution Medicines media release, initial clinical results for daraxonrasib in first line metastatic pancreatic ductal adenocarcinoma support planned three-arm Phase 3 trial which is expected to began in Q4 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top